Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: A meta-analysis

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Zuo, Pei Yuan ^a   Chen, Xing Lin ^a   Liu, Yu Wei ^a   Xiao, Chang Liang ^a   Liu, Cheng Yun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLACEBO; PREDNISONE; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BREAST CANCER; CANCER GRADING; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; GLIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MELANOMA; MESOTHELIOMA; META ANALYSIS; OVARY CANCER; PERITONEUM CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STOMACH CANCER; SYSTEMATIC REVIEW; THROMBOEMBOLISM; CHEMICALLY INDUCED; INTRACRANIAL HEMORRHAGES; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; STROKE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTRACRANIAL HEMORRHAGES; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 84904262616     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102484     Document Type: Article

References (39)

1. Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, et al. (2013) Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 18: 872-879.
2. Schutz FA, Je Y, Azzi GR, Nguyen PL, Choueiri TK (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 22: 1404-1412.
3. Hapani S, Sher A, Chu D, Wu S (2010) Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology 79: 27-38.
4. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239. (Pubitemid 47299901)
5. Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49: 287-297.
6. Carden CP, Larkin JM, Rosenthal MA (2008) What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 10: 624-630.
7. Letarte N, Bressler LR, Villano JL (2013) Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol 71: 1561-1565.
8. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, et al. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722.
9. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, et al. (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30: 1534-1540.
10. Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, et al. (2012) Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Ann Oncol 23: 1531-1536.
11. Okines AF, Langley RE, Thompson LC, Stenning SP, Stevenson L, et al. (2013) Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Ann Oncol 24: 702-709.
12. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, et al. (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30: 2039-2045.
13. NCI. National Cancer institute's common toxicity criteria. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/ctc.htm. Accessed 26 February 2014.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550. (Pubitemid 44917502)
16. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, et al. (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676.
17. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. JOURNAL OF CLINICAL ONCOLOGY 25: 1539-1544. (Pubitemid 46733080)
18. Kindler HL, Karrison T, Gandara DR, Lu C, Guterz TL, et al. (2007) Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma. JOURNAL OF THORACIC ONCOLOGY 2S: S374.
19. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Colangelo LH, et al. (2009) Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol 27: 3385-3390.
20. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, et al. (2010) Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 28: 2137-2143.
21. Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, et al. (2010) Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28: 3617-3622.
22. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, et al. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. LANCET 377: 1846-1854.
23. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, et al. (2012) BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 30: 34-41.
24. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, et al. (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365: 2473-2483.
25. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, et al. (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365: 2484-2496.
26. Meade MO, Richardson WS (1997) Selecting and appraising studies for a systematic review. Ann Intern Med 127: 531-537. (Pubitemid 27419445)
27. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560. (Pubitemid 37088507)
28. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188. (Pubitemid 17189972)
29. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
30. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
31. Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, et al. (2013) Angiogenesis Inhibitor Bevacizumab Increases the Risk of Ischemic Heart Disease Associated with Chemotherapy: A Meta-Analysis. PLOS ONE 8.
32. Seet RC, Rabinstein AA, Lindell PE, Uhm JH, Wijdicks EF (2011) Cerebrovascular events after bevacizumab treatment: an early and severe complication. Neurocrit Care 15: 421-427.
33. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795. (Pubitemid 46912024)
34. Zachary I (2001) Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280: C1375-C1386.
35. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23: 460-468.
36. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49: 186-193. (Pubitemid 46178407)
37. Meyerhardt JA, Li L, Sanoff HK, Carpenter WT, Schrag D (2012) Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 30: 608-615.
38. Becker J, Pavlakovic H, Ludewig F, Wilting F, Weich HA, et al. (2010) Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res 16: 1431-1441.
39. Narita Y (2013) Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Jpn J Clin Oncol 43: 587-595.